Publikationen (13) Publikationen von FRANCISCO ESPEJO PORRAS

2023

  1. Chronic nSMase inhibition suppresses neuronal exosome spreading and sex-specifically attenuates amyloid pathology in APP knock-in Alzheimer's disease mice

    Neurobiology of Disease, Vol. 184

2021

  1. Targeting the CB2 receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis

    British Journal of Pharmacology, Vol. 178, Núm. 6, pp. 1373-1387

2020

  1. Elevated exosomal secretion of miR-124-3p from spinal neurons positively associates with disease severity in ALS

    Experimental Neurology, Vol. 333

  2. Pharmacokinetics of sativex® in dogs: Towards a potential cannabinoid-based therapy for canine disorders

    Biomolecules, Vol. 10, Núm. 2

2019

  1. Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis

    British Journal of Pharmacology, Vol. 176, Núm. 10, pp. 1585-1600

2018

  1. Analysis of endocannabinoid receptors and enzymes in the post-mortem motor cortex and spinal cord of amyotrophic lateral sclerosis patients

    Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, Vol. 19, Núm. 5-6, pp. 377-386

  2. Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis

    Biochemical Pharmacology, Vol. 157, pp. 217-226

2017

  1. Upregulation of CB2 receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis

    DMM Disease Models and Mechanisms, Vol. 10, Núm. 5, pp. 551-558

2015

  1. Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders

    Journal of Neuroimmune Pharmacology, Vol. 10, Núm. 2, pp. 233-244

  2. Endocannabinoids and amyotrophic lateral sclerosis

    Cannabinoids in Neurologic and Mental Disease (Elsevier Inc.), pp. 99-123

  3. The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Δ9-tetrahydrocannabinol acting through CB1 receptors

    Multiple Sclerosis and Related Disorders, Vol. 4, Núm. 6, pp. 505-511

2014

  1. Changes in endocannabinoid receptors and enzymes in the spinal cord of sod1g93a transgenic mice and evaluation of a sativex®-like combination of phytocannabinoids: Interest for future therapies in amyotrophic lateral sclerosis

    CNS Neuroscience and Therapeutics, Vol. 20, Núm. 9, pp. 809-815

2013

  1. Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors

    Neuropharmacology, Vol. 75, pp. 155-163